Virus-mediated EpoR76E therapy slows optic nerve axonopathy in experimental glaucoma

Molecular Therapy

Volumn 24, Issue 2, 2016, Pages 230-239

  Bond, Wesley S ^a,b   Hines Beard, Jessica ^a,b   Goldenmerry, YPaul L ^a   Davis, Mara ^a   Farooque, Alma ^a   Sappington, Rebecca M ^a,b   Calkins, David J ^a,b   Rex, Tonia S ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; ERYTHROPOIETIN RECEPTOR 76E; PARVOVIRUS VECTOR; UNCLASSIFIED DRUG; EPO PROTEIN, HUMAN;

ACTIVE TRANSPORT; ADENO ASSOCIATED VIRUS 2; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRUCTURE; CONTROLLED STUDY; DBA 2 MOUSE; DISEASE MODEL; DRUG EFFICACY; ERYTHROPOIESIS; EVOKED VISUAL RESPONSE; EXPERIMENTAL GLAUCOMA; GLAUCOMA; GLAUCOMATOUS OPTIC NEUROPATHY; HEMATOCRIT; INTRAOCULAR PRESSURE; MALE; MICROBEAD OCCLUSION MODEL; MOUSE; MOUSE MODEL; NERVE FIBER; NERVE FIBER TRANSPORT; NEUROPROTECTION; NONHUMAN; OPTIC NERVE; RETINA GANGLION CELL; SINGLE DRUG DOSE; SYSTEMIC THERAPY; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS RECOMBINANT; VISION; ADMINISTRATION AND DOSAGE; ANIMAL; AXON; DEPENDOPARVOVIRUS; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; MUTATION; PATHOLOGY;

ANIMALS; AXONS; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; ERYTHROPOIETIN; GENETIC THERAPY; GENETIC VECTORS; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; MICE; MUTATION; OPTIC NERVE;

EID: 84959465031     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2015.198     Document Type: Article

References (41)

1. Schwartz, K and Budenz, D (2004). Current management of glaucoma. Curr Opin Ophthalmol 15: 119-126.
2. Olthoff, CM, Schouten, JS, van de Borne, BW and Webers, CA (2005). Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology 112: 953-961.
3. Broxmeyer, HE (2013). Erythropoietin: multiple targets, actions and modifying influences for biological and clinical consideration. J Exp Med 210: 205-208.
4. Noguchi, CT, Asavaritikrai, P, Teng, R and Jia, Y (2007). Role of erythropoietin in the brain. Crit Rev Oncol Hematol 64: 159-171.
5. Bond, WS and Rex, TS (2014). Evidence that erythropoietin modulates neuroinflammation through differential action on neurons, astrocytes and microglia. Front Immunol 5: 523.
6. Salmonson, T, Danielson, BG and Wikström, B (1990). The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects. Br J Clin Pharmacol 29: 709-713.
7. Sullivan, TA, Geisert, EE, Hines-Beard, J and Rex, TS (2011). Systemic adeno-Associated virus-mediated gene therapy preserves retinal ganglion cells and visual function in DBA/2J glaucomatous mice. Hum Gene Ther 22: 1191-1200.
8. Sullivan, T, Kodali, K and Rex, TS (2011). Systemic gene delivery protects the photoreceptors in the retinal degeneration slow mouse. Neurochem Res 36: 613-618.
9. Sullivan, TA, Geisert, EE, Templeton, JP and Rex, TS (2012). Dose-Dependent treatment of optic nerve crush by exogenous systemic mutant erythropoietin. Exp Eye Res 96: 36-41.
10. Rex, TS, Allocca, M, Domenici, L, Surace, EM, Maguire, AM, Lyubarsky, A, et al. (2004). Systemic but not intraocular Epo gene transfer protects the retina from light-And genetic-induced degeneration. Mol Ther 10: 855-861.
11. Dhanushkodi, A, Akano, EO, Roguski, EE, Xue, Y, Rao, SK, Matta, SG, et al. (2013). A single intramuscular injection of rAAV-mediated mutant erythropoietin protects against MPTP-induced parkinsonism. Genes Brain Behav 12: 224-233.
12. Hines-Beard, J, Desai, S, Haag, R, Esumi, N, D'Surney, L, Parker, S, et al. (2013). Identification of a therapeutic dose of continuously delivered erythropoietin in the eye using an inducible promoter system. Curr Gene Ther 13: 275-281.
13. Sappington, RM, Carlson, BJ, Crish, SD and Calkins, DJ (2010). The microbead occlusion model: a paradigm for induced ocular hypertension in rats and mice. Invest Ophthalmol Vis Sci 51: 207-216.
14. Ward, NJ, Ho, KW, Lambert, WS, Weitlauf, C and Calkins, DJ (2014). Absence of transient receptor potential vanilloid-1 accelerates stress-induced axonopathy in the optic projection. J Neurosci 34: 3161-3170.
15. Mo, JS, Anderson, MG, Gregory, M, Smith, RS, Savinova, OV, Serreze, DV, et al. (2003). By altering ocular immune privilege, bone marrow-Derived cells pathogenically contribute to DBA/2J pigmentary glaucoma. J Exp Med 197: 1335-1344.
16. Buckingham, BP, Inman, DM, Lambert, W, Oglesby, E, Calkins, DJ, Steele, MR, et al. (2008). Progressive ganglion cell degeneration precedes neuronal loss in a mouse model of glaucoma. J Neurosci 28: 2735-2744.
17. Crish, SD, Sappington, RM, Inman, DM, Horner, PJ and Calkins, DJ (2010). Distal axonopathy with structural persistence in glaucomatous neurodegeneration. Proc Natl Acad Sci USA 107: 5196-5201.
18. Calkins, DJ (2012). Critical pathogenic events underlying progression of neurodegeneration in glaucoma. Prog Retin Eye Res 31: 702-719.
19. John, SW, Smith, RS, Savinova, OV, Hawes, NL, Chang, B, Turnbull, D, et al. (1998). Essential iris atrophy, pigment dispersion and glaucoma in DBA/2J mice. Invest Ophthalmol Vis Sci 39: 951-962.
20. Havenaar, R, Meijer, JC, Morton, DB, Ritskes-Hoitinga, J and Zwart, P (2001). Biology and husbandry of laboratory animals. In: Van Zutphen LFM, Baumans V, Baynen AC (eds). Principles of Laboratory Animal Science, revised edn. Elsevier Science: Amsterdam. pp. 19-28.
21. Crish, SD, Dapper, JD, MacNamee, SE, Balaram, P, Sidorova, TN, Lambert, WS, et al. (2013). Failure of axonal transport induces a spatially coincident increase in astrocyte BDNF prior to synapse loss in a central target. Neuroscience 229: 55-70.
22. Dapper, JD, Crish, SD, Pang, IH and Calkins, DJ (2013). Proximal inhibition of p38 MAPK stress signaling prevents distal axonopathy. Neurobiol Dis 59: 26-37.
23. Lambert, WS, Ruiz, L, Crish, SD, Wheeler, LA and Calkins, DJ (2011). Brimonidine prevents axonal and somatic degeneration of retinal ganglion cell neurons. Mol Neurodegener 6: 4.
24. Zincarelli, C, Soltys, S, Rengo, G and Rabinowitz, JE (2008). Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 16: 1073-1080.
25. Inman, DM, Sappington, RM, Horner, PJ and Calkins, DJ (2006). Quantitative correlation of optic nerve pathology with ocular pressure and corneal thickness in the DBA/2 mouse model of glaucoma. Invest Ophthalmol Vis Sci 47: 986-996.
26. Chou, TH, Kocaoglu, OP, Borja, D, Ruggeri, M, Uhlhorn, SR, Manns, F, et al. (2011). Postnatal elongation of eye size in DBA/2J mice compared with C57BL/6J mice: in vivo analysis with whole-Eye OCT. Invest Ophthalmol Vis Sci 52: 3604-3612.
27. Anderson, MG, Libby, RT, Gould, DB, Smith, RS and John, SW (2005). High-Dose radiation with bone marrow transfer prevents neurodegeneration in an inherited glaucoma. Proc Natl Acad Sci USA 102: 4566-4571.
28. Schlamp, CL, Li, Y, Dietz, JA, Janssen, KT and Nickells, RW (2006). Progressive ganglion cell loss and optic nerve degeneration in DBA/2J mice is variable and asymmetric. BMC Neurosci 7: 66.
29. Sappington, RM, Chan, M and Calkins, DJ (2006). Interleukin-6 protects retinal ganglion cells from pressure-induced death. Invest Ophthalmol Vis Sci 47: 2932-2942.
30. Howell, GR, Soto, I, Zhu, X, Ryan, M, Macalinao, DG, Sousa, GL, et al. (2012). Radiation treatment inhibits monocyte entry into the optic nerve head and prevents neuronal damage in a mouse model of glaucoma. J Clin Invest 122: 1246-1261.
31. Johnson, EC, Cepurna, WO, Choi, D, Choe, TE and Morrison, JC (2015). Radiation pretreatment does not protect the rat optic nerve from elevated intraocular pressureinduced injury. Invest Ophthalmol Vis Sci 56: 412-419.
32. Chrysostomou, V, Rezania, F, Trounce, IA and Crowston, JG (2013). Oxidative stress and mitochondrial dysfunction in glaucoma. Curr Opin Pharmacol 13: 12-15.
33. Tezel, G, Yang, X, Luo, C, Kain, AD, Powell, DW, Kuehn, MH, et al. (2010). Oxidative stress and the regulation of complement activation in human glaucoma. Invest Ophthalmol Vis Sci 51: 5071-5082.
34. Zanon-Moreno, V, Marco-Ventura, P, Lleo-Perez, A, Pons-Vazquez, S, Garcia-Medina, JJ, Vinuesa-Silva, I, et al. (2008). Oxidative stress in primary open-Angle glaucoma. J Glaucoma 17: 263-268.
35. Ghanem, AA, Arafa, LF and El-Baz, A (2010). Oxidative stress markers in patients with primary open-Angle glaucoma. Curr Eye Res 35: 295-301.
36. Harwerth, RS, Carter-Dawson, L, Shen, F, Smith, EL 3rd and Crawford, ML (1999). Ganglion cell losses underlying visual field defects from experimental glaucoma. Invest Ophthalmol Vis Sci 40: 2242-2250.
37. Coleman, AL and Miglior, S (2008). Risk factors for glaucoma onset and progression. Surv Ophthalmol 53 (suppl. 1): S3-10.
38. Bosco, A, Steele, MR and Vetter, ML (2011). Early microglia activation in a mouse model of chronic glaucoma. J Comp Neurol 519: 599-620.
39. Fernández-Sánchez, L, de Sevilla Müller, LP, Brecha, NC and Cuenca, N (2014). Loss of outer retinal neurons and circuitry alterations in the DBA/2J mouse. Invest Ophthalmol Vis Sci 55: 6059-6072.
40. de Lucas Cerrillo, AM, Bond, WS and Rex, TS (2015). Safety and angiogenic effects of systemic gene delivery of a modified erythropoietin. Gene Ther 22: 365-373.
41. Louboutin, JP, Wang, L and Wilson, JM (2005). Gene transfer into skeletal muscle using novel AAV serotypes. J Gene Med 7: 442-451.